# MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes

> **NCT01847144** · PHASE4 · COMPLETED · sponsor: **Royal Devon and Exeter NHS Foundation Trust** · enrollment: 143 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Gliclazide 80mg OD
- **DRUG:** Sitagliptin 100mg OD

## Key facts

- **NCT ID:** NCT01847144
- **Lead sponsor:** Royal Devon and Exeter NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2018-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01847144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01847144, "MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01847144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*